ZYGK1

ZYGK1 is a novel small molecule glucokinase activator developed for the treatment of type 2 diabetes. It acts by stimulating glucokinase activity in both the liver and pancreas, thereby enhancing glucose utilization and promoting glucose-dependent insulin secretion. Preclinical studies have shown that ZYGK1 increases glucokinase activity in islets and hepatocytes with an EC50 of 43 nM, improves glucose disposal in oral glucose tolerance tests, and enhances glycemic control even in sulfonylurea-resistant models. The drug is administered orally and has demonstrated a favorable safety profile in preclinical models. Clinical development has reached phase 1 trials to evaluate its safety, tolerability, and pharmacokinetics[1][3][4].

Other names

Glucokinase activator (oral, diabetes)